Personalized briefing
Discovery of the day · Neurology
[Series] Fluid biomarkers in the evolving care landscape of Alzheimer’s disease and related disorders
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
A Lancet Neurology series reports that ultrasensitive and multiplexing technologies, alongside high-specificity antibodies, have enabled blood-based biomarkers — notably neurofilament light for frontotemporal dementia and amyotrophic lateral sclerosis, and phosphorylated tau 217 for Alzheimer’s disease — to enter routine clinical practice. These assays now provide diagnostic specificity previously attainable only through cerebrospinal fluid or positron emission tomography, allowing detection of neuroaxonal injury and amyloid-associated tau pathology via peripheral blood. For a neuroscience researcher working on preclinical models of chronic pain and placebo analgesia at the Brain and Mind Centre, this biomarker framework illustrates how a validated peripheral signal can translate a complex central nervous system pathology into a clinically actionable measure — a methodological template that is directly transferable to pain phenotyping and stratification.
Novelty
82%
Rigor
88%
Significance
93%
Validity
85%
Clarity
90%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
